Trial Profile
An Open-Label, Multicohort, Phase II Study of Atezolizumab in Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Lung cancer; Male breast cancer; Malignant thymoma; Malignant-mesothelioma; Nasopharyngeal cancer; Neuroendocrine tumours; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma; Solid tumours; Squamous cell cancer; Thyroid cancer
- Focus Therapeutic Use
- Acronyms Basket
- Sponsors Roche
- 24 Aug 2020 Status changed from active, no longer recruiting to completed.
- 05 May 2020 Planned End Date changed from 21 Mar 2020 to 30 Jun 2020.
- 28 Apr 2020 This trial has been completed in Austria.